|
Colorectal Carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
IHC was performed on tissue microarrays containing 2823 consecutive CRC undergoing surgery with curative intent using a novel mutation-specific antibody to the protein produced by the NRAS mutation (clone SP174).
|
26862952 |
2017 |
|
Juvenile Myelomonocytic Leukemia
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Gain-of-function variants in some RAS-MAPK pathway genes, including PTPN11 and NRAS, are associated with RASopathies and/or acquired hematological malignancies, most notably juvenile myelomonocytic leukemia (JMML).
|
28098151 |
2017 |
|
Colorectal Carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
Cetuximab plus chemotherapy is a first-line treatment option in metastatic KRAS and NRAS wild-type colorectal cancer (CRC) patients.
|
27002107 |
2016 |
|
Colorectal Carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Testing for NRAS mutation at codon Q61 is of therapeutic, prognostic, and diagnostic importance for metastatic melanoma, thyroid carcinoma, and colorectal carcinoma.
|
26712868 |
2016 |
|
Colorectal Carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
Five nonsynonymous germline variants on 4 cancer susceptible genes, CDH1, APC, MLH1, and NRAS, were observed in 6 patients with CRC (12%).
|
27121310 |
2016 |
|
Colorectal Carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
The clinicopathologic features and frequency of KRAS mutations in colorectal cancer (CRC) patients have been reported; however, the characteristics and impact of NRAS and HRAS mutations on the survival of CRC patients have seldom been addressed.
|
27394063 |
2016 |
|
Colorectal Carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
We selected one hundred and twenty eight patients diagnosed with advanced colorectal cancer with a KRAS and NRAS unmutated tumor.
|
26824184 |
2016 |
|
Colorectal Carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
As a group, CRC complicating Crohn's colitis is BRAF (97 %) and NRAS (100 %) wild type and the vast majority is microsatellite stable (94 %); KRAS-mutations were found in six cases (18 %).
|
27026089 |
2016 |
|
Juvenile Myelomonocytic Leukemia
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
We further evaluated the anti-proliferative potential of GMR CAR T cells on leukemic CD34(+) cells from six patients with JMML (two NRAS mutations, three PTPN11 mutations, and one monosomy 7), and normal CD34(+) cells.
|
26983639 |
2016 |
|
Juvenile Myelomonocytic Leukemia
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
This case highlights an NRAS mutation in ETP-ALL with JMML-like phenotype.
|
27145535 |
2016 |
|
Colorectal Carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
This expert group recommends testing for KRAS and NRAS status in all patients with metastatic CRC being considered for anti-epidermal growth factor receptor (anti-EGFR) therapy, as this type of treatment should only be used in patients not harbouring mutations in these genes.
|
25373533 |
2015 |
|
Colorectal Carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
Somatic mutations in KRAS, NRAS, and BRAF genes are related to resistance to anti-EGFR antibodies in colorectal cancer.
|
25954997 |
2015 |
|
Colorectal Carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
In advanced colorectal carcinoma (CRC) patients, extended RAS mutations testing (KRAS exons 2 to 4 and NRAS exons 2 to 4) is a prerequisite for patient stratification to anti-EGFr therapy.
|
26163758 |
2015 |
|
Colorectal Carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
NRAS mutations occur in 3-5% of colorectal cancer.
|
24806288 |
2015 |
|
Colorectal Carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
The clinically relevant genetic aberrations described in this review include mutation analyses of RAS (KRAS and NRAS), BRAF and PI3K in colorectal cancer, KIT or PDGFR alpha as well as BRAF, NRAS and KIT in malignant melanoma.
|
26358176 |
2015 |
|
Colorectal Carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
RAS (KRAS and NRAS) testing is required to predict anti-epidermal growth factor receptor (EGFR) treatment efficacy in metastatic colorectal cancer (CRC).
|
26137573 |
2015 |
|
Colorectal Carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
According to current clinical guidelines mutational analysis for KRAS and NRAS is recommended prior to EGFR-directed therapy of colorectal cancer (CRC) in the metastatic setting.
|
26220423 |
2015 |
|
Colorectal Carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Japanese Society of Medical Oncology Clinical Guidelines: RAS (KRAS/NRAS) mutation testing in colorectal cancer patients.
|
25800101 |
2015 |
|
Juvenile Myelomonocytic Leukemia
|
0.800 |
Biomarker
|
disease |
CTD_human |
The genomic landscape of juvenile myelomonocytic leukemia.
|
26457647 |
2015 |
|
Juvenile Myelomonocytic Leukemia
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
We recommend that this option be promptly offered to any child with PTPN-11-, K-RAS-, or NF1-mutated JMML and to the majority of those with N-RAS mutations.
|
25564399 |
2015 |
|
Juvenile Myelomonocytic Leukemia
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
RALD has clinical and laboratory features that overlap with those of juvenile myelomonocytic leukemia (JMML) and chronic myelomonocytic leukemia (CMML), including identical somatic mutations in KRAS or NRAS genes noted in peripheral blood mononuclear cells.
|
25691160 |
2015 |
|
Juvenile Myelomonocytic Leukemia
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Neither of affected individuals in this family presented with juvenile myelomonocytic leukemia (JMML), which together with previously published results suggest that the risk for NS individuals with a germline NRAS mutation developing JMML is not different from the proportion seen in other NS cases.
|
26467218 |
2015 |
|
Colorectal Carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Characteristics and prognosis of CRC with NRAS mutations are different from those with KRAS or BRAF mutations.
|
24806883 |
2014 |
|
Colorectal Carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Recent studies have demonstrated that, in advanced colorectal carcinoma (CRC) patients, extended RAS (in KRAS exons 2-4 and NRAS exons 2-4) and BRAF mutations are negative predictors for anti-EGFR treatment efficacy and negative prognostic factor, respectively.
|
25262986 |
2014 |
|
Colorectal Carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
The added predictive value of additional biomarkers in the RAS-RAF-MAPK and PI3K-AKT-mTOR pathways in colorectal cancer is uncertain, which led us to systematically review the impact of alterations in KRAS (outside of exon 2), NRAS, BRAF, PIK3CA and PTEN in relation to the clinical benefit from anti-EGFR treatment.
|
24666267 |
2014 |